Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

NCT05498597 : First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

OnePhase One

18+Age Over 18

Advanced CancersCancer LocationMulti-Cancer
Trial

Systemic therapy | Breast,Female reproductive organs,Lung,Stomach and upper gastrointestinal tractBreast,Endometrium,Fallopian tube,Lung,Mesothelioma,Ovary,Pancreas,Peritoneal

Trial Overview Read MoreRead more

This phase I study is seeking to determine the best dose level, safety and effectiveness of a new cancer treatment (AMT-151) in people with certain advanced solid cancers.
 

This trial is treating patients with advanced serous, endometrioid, clear-cell, or mucinous epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; serous, endometrioid, or clear-cell endometrial cancer; adenocarcinoma of the lung; triple-negative breast cancer; pancreatic ductal adenocarcinoma; and malignant pleural mesothelioma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

Commercial Sponsor

Multitude Therapeutics Inc.

Summary

Eligible participants will receive AMT-151 intravenously (via IV).

Recruiting Hospitals Read MoreRead more

Cabrini Education and Research Precinct
Malvern
Clinical Trials Enquiries
clinicaltrials@cabrini.com.au

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next